High Throughput Process Development Market at a CAGR of 14.4% from 2016 to 2021.

According to the new market research report HighThroughput Process Development Market by Product(Consumables (Minicolumn, Mini Bioreactor), Instruments), Services, Software,Molecule Type (mAB), Technology (Affinity Chromatography), End User(Biopharmaceutical) – ****** Forecast to 2021″, published byMarketsandMarkets™, analyzes andstudies the major market drivers, restraints/challenges, and opportunities.

Growth in the high throughput process development market is mainly driven by increasing R&D spending, technological advancements in process development, growth in the biopharmaceutical industry, and the increasing pressure to lower manufacturing costs.
By molecule type, the high throughput process development market is classified into monoclonal antibodies and others (recombinant pro-insulin, polysaccharide vaccines, recombinant Green Fluorescent Protein (rGFP), fusion proteins, and interferon á-2a). The monoclonal antibodies segment accounted for the largest share of the ****** market in 2016. The large share of this segment is attributed to the increasing adoption of targeted immunotherapy and the increasing number of FDA-cleared therapeutic monoclonal antibodies.

 Browse and in-depth TOC on ” High Throughput Process Development Market”
102 – Tables
35 – Figures
152 – Pages
View more detailed TOC @
https://www.marketsandmarkets.com/Market-Reports/high-throughput-process-development-market-10249359.html

Based on end user, the market is categorized into biopharmaceutical companies, contract research organizations and academic research institutes. Biopharmaceutical companies accounted for the largest share of the ****** high throughput process development market in 2016. The contract manufacturing organizations segment, on the other hand, is expected to be the fastest-growing end-user segment of the market during the forecast period. High R&D investments by pharmaceutical and biopharmaceutical companies to accelerate drug manufacturing and increasing pressure from regulatory authorities to lower the cost of production are the major factors driving the growth of the biopharmaceutical manufacturers end-user segment.

Based on technology, the market is categorized into chromatography, ultraviolet-visible spectroscopy, and others (ELISA, chip electrophoresis, SPR, and qPCR). The chromatography segment accounted for the largest share of the ****** high throughput process development market in 2016. The chromatography segment is further divided into ion exchange chromatography (IEC), affinity chromatography (AC), multimodal chromatography (MC), and others (hydrophobic charge induction chromatography (HCIC) and size exclusion chromatography). The affinity chromatography segment accounted for the largest share of the chromatography high throughput process development in 2016. Owing to the advantages of affinity chromatography over other chromatography such as high selectivity, high flow rate and its capacity for extensive removal of process-related impurities such as host cell proteins, DNA, and cell culture media component are driving the growth of the market.

Discount Available on Report @ https://www.marketsandmarkets.com/discountreports.asp?id=10249359

Factors such as the high cost of technology and equipment in this market and the la          ck of adequate infrastructural facilities are restraining the growth of this market to a certain extent.
Geographically, North America (comprising the US and Canada) accounted for the largest share of the ****** high throughput process development market in 2016. Factors such as increasing R&D spending by pharmaceutical and biopharmaceutical companies, growing demand for technical tools for improving the production quality of biological materials, collective pressure towards lowering the cost of manufacturing biological materials, rising demand for reducing product development timelines, and the presence of major players in this region are driving the growth of the North American market.

Key Players
Major players operating in the high throughput process development market include Danaher (US), GE Healthcare (US), Agilent Technologies (US), Merck Millipore (Germany), and Thermo Fisher Scientific (US).

Adjacent Markets Report Available – Request for bundle reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=10249359